H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Cocrystal Pharma to $7 from $10 and keeps a Buy rating on the shares. The analyst cites projected equity dilution for the target cut post the Q2 report.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COCP:
- Cocrystal Pharma Engages Investors at Upcoming Conferences
- Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences
- Cocrystal Pharma reports Q2 EPS (54c), consensus (48c)
- COCP Upcoming Earnings Report: What to Expect?
- Cocrystal Pharma reports results from SAD cohorts of Phase 1 study with CDI-988